Compass Therapeutics Bile Cancer Treatment Doesn't Meet Overall Survival Goal

Dow Jones

04/27

By Katherine Hamilton

Compass Therapeutics said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival.

Shares fell 23% to $3.85 in premarket trading Monday. Through Friday's close, the stock was down 6% this year.

Compass' trial was studying tovecimig plus paclitaxel as a treatment of biliary tract cancer, which affects the bile ducts or gallbladder.

Tovecimig showed a clinically meaningful and statistically significant improvement in progression-free survival. It reduced the risk of disease progression by 56%.

It didn't meet the overall survival endpoint, however, due to high crossover from the control arm. About 54% of patients crossed over from the control group to receive the treatment that was being studied in the trial.

Because of the high crossover rate, the data from the trial are uninterpretable, Compass said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

April 27, 2026 08:08 ET (12:08 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2630967713"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2630967713\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2630967713?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-27 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630967713","market":"us","top_or_hot":-1,"title":"Compass Therapeutics Bile Cancer Treatment Doesn't Meet Overall Survival Goal","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Compass <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival. \n</p>\n<p>\n  Shares fell 23% to $3.85 in premarket trading Monday. Through Friday's close, the stock was down 6% this year. \n</p>\n<p>\n  Compass' trial was studying tovecimig plus paclitaxel as a treatment of biliary tract cancer, which affects the bile ducts or gallbladder. \n</p>\n<p>\n  Tovecimig showed a clinically meaningful and statistically significant improvement in progression-free survival. It reduced the risk of disease progression by 56%. \n</p>\n<p>\n  It didn't meet the overall survival endpoint, however, due to high crossover from the control arm. About 54% of patients crossed over from the control group to receive the treatment that was being studied in the trial. \n</p>\n<p>\n  Because of the high crossover rate, the data from the trial are uninterpretable, Compass said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 27, 2026 08:08 ET (12:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Compass Therapeutics Bile Cancer Treatment Doesn't Meet Overall Survival Goal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompass Therapeutics Bile Cancer Treatment Doesn't Meet Overall Survival Goal\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-04-27 20:08</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Compass <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival. \n</p>\n<p>\n  Shares fell 23% to $3.85 in premarket trading Monday. Through Friday's close, the stock was down 6% this year. \n</p>\n<p>\n  Compass' trial was studying tovecimig plus paclitaxel as a treatment of biliary tract cancer, which affects the bile ducts or gallbladder. \n</p>\n<p>\n  Tovecimig showed a clinically meaningful and statistically significant improvement in progression-free survival. It reduced the risk of disease progression by 56%. \n</p>\n<p>\n  It didn't meet the overall survival endpoint, however, due to high crossover from the control arm. About 54% of patients crossed over from the control group to receive the treatment that was being studied in the trial. \n</p>\n<p>\n  Because of the high crossover rate, the data from the trial are uninterpretable, Compass said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 27, 2026 08:08 ET (12:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMPX","symbol_name":"Compass Therapeutics, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2630967713","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2630967713","pubTimestamp":1777291680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Compass Therapeutics said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival.Shares fell 23% to $3.85 in premarket trading Monday. Through Friday's close, the stock was down 6% this year.Compass' trial was studying tovecimig plus paclitaxel as a treatment of biliary tract cancer, which affects the bile ducts or gallbladder.Tovecimig showed a clinically meaningful and statistically significant improvement in progression-free survival. It reduced the risk of disease progression by 56%.It didn't meet the overall survival endpoint, however, due to high crossover from the control arm. About 54% of patients crossed over from the control group to receive the treatment that was being studied in the trial.Because of the high crossover rate, the data from the trial are uninterpretable, Compass said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMPX":"Compass Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Compass Therapeutics胆汁癌治疗未达到总生存目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMPX":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Compass Therapeutics said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival. \n\n\n  Shares fell 23% to $3.85 in premarket trading Monday. Through Friday's close, the stock was down 6% this year. \n\n\n  Compass' trial was studying tovecimig plus paclitaxel as a treatment of biliary tract cancer, which affects the bile ducts or gallbladder. \n\n\n  Tovecimig showed a clinically meaningful and statistically significant improvement in progression-free survival. It reduced the risk of disease progression by 56%. \n\n\n  It didn't meet the overall survival endpoint, however, due to high crossover from the control arm. About 54% of patients crossed over from the control group to receive the treatment that was being studied in the trial. \n\n\n  Because of the high crossover rate, the data from the trial are uninterpretable, Compass said. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 27, 2026 08:08 ET (12:08 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}